Literature DB >> 1202621

CEA levels at recurrence and metastases; importance for detecting secondary disease.

A Rieger, B Wahren.   

Abstract

The relation of CEA plasma levels to prognostic factors was studied in 170 patients with various stages of colo-rectal cancer. Several parameters of known relevance for the prognosis were analyzed. Among the patients with involvement of regional lymph nodes at the time of the primary, 53% had a raised CEA value (greater than 5 ng/ml serum) as opposed to 21% when this was not the case (p less than 0.05%). When serosal break-through had occured, 47% of the patients had raised values compared to 21% of those with no serosal break-through (p less than 0.02%). After radical surgery, all patients who remained healthy acquired persistent low plasma CEA, giving the assay a prognostic value. Altogether 20 patients had local recurrences without distant metastases and were thus potential candidates for a re-operation for cure. 70% had raised CEA plasma values, giving the assay a better than expected usefulness in the clinical follow-up, the significance of the difference from operated and healthy patients or healthy control persons being high, p less than 0.001%. The secondary rise in CEA appeared to be unconnected with whether or not the primary tumor had been accompanied by raised plasma CEA. The localization and the histopathological differentiation of the primary tumor seemed to be of less importance for the serum CEA than the dissemination of the tumor.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1202621

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

1.  Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients.

Authors:  Kristina Schee; Kjersti Flatmark; Ruth Holm; Kjetil Boye; Elisabeth Paus
Journal:  Tumour Biol       Date:  2011-10-18

2.  The usefulness and limitations of CEA assay in the management of colorectal cancer.

Authors:  H Tomoda; M Furusawa
Journal:  Jpn J Surg       Date:  1981-01

3.  Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer.

Authors:  E Polat; U Duman; M Duman; A E Atici; E Reyhan; T Dalgic; E B Bostanci; S Yol
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

4.  Carcinoembryonic antigen (CEA) levels in patients with brain tumours.

Authors:  E Miyake; M Yamashita; K Kitamura; F Ishigami
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

Review 5.  Carcinoembryonic antigen in patients with breast or colon cancer.

Authors:  Y N Lee
Journal:  West J Med       Date:  1978-11

6.  The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells.

Authors:  Chang Yan; Yibing Hu; Bo Zhang; Lei Mu; Kaiyu Huang; Hui Zhao; Chensen Ma; Xiaolan Li; Deding Tao; Jianping Gong; Jichao Qin
Journal:  Oncotarget       Date:  2016-12-06

Review 7.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

8.  Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer.

Authors:  M Li; J-Y Li; A-L Zhao; J-S He; L-X Zhou; Y-A Li; J Gu
Journal:  Colorectal Dis       Date:  2008-05-29       Impact factor: 3.788

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.